Release details

2016-01-06 22:16 CET
  • Print
  • Share Share
en

uniQure Announces Conference Call and Webcast to Discuss Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial

Amsterdam, the Netherlands, January 6, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that the Company will release topline results from its Hemophilia B Phase I/II gene therapy low-dose cohort clinical trial through a press release at 06:00 EST/12:00 CET on January 7, 2016.  The Company's management team will hold a conference call and webcast at 08:30 EST/14:30 CET after the press release has been issued to discuss the update.

The conference call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code: 1640435. The webcast, including accompanying slides also available as a PDF file, can be accessed through the link displayed in the "Events" section on the "Media" page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/. The webcast replay will be available for at least 72 hours following the call.

Conference Call Numbers

London, United Kingdom:   +44 (0) 20 3427 1906
New York, United States of America:   +1 212 444 0412
Berlin, Germany:   +49 (0) 30 3001 90534
Amsterdam, Netherlands:   +31 (0) 20 716 8296
Paris, France:   +33 (0) 1 76 77 22 31
Milan, Italy:   +39 02 3859 1420
Brussels, Belgium:   +32 (0) 2 402 3092
Montreal, Canada:   +1 514 841 2154

About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com

CONTACT
uniQure:                                                          
Direct: +31 20 240 6110
Main: +31 20 240 6000
e.mulder@uniQure.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or
+1 781 235 3060
gschweitzer@macbiocom.com

HUG#1977179